Cargando…
OA04-01. Safety and immunogenicity of LIPO-5, a HIV-1 lipopeptide vaccine: results of ANRS VAC18, a phase 2, randomized, double-blind, placebo-controlled trial
Autores principales: | Salmon-Céron, D, Durier, C, Desaint, C, Cuzin, Surenaud, M, Hénin, Y, Lelièvre, J, Bonnet, B, Pialoux, G, Poizot-Martin, I, Ben Hamouda, N, Jackson, A, Flys, C, Guérin, C, Aboulker, J, Choppin, J, Launay, O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767546/ http://dx.doi.org/10.1186/1742-4690-6-S3-O25 |
Ejemplares similares
-
Cellular Immune Responses Induced with Dose-Sparing Intradermal Administration of HIV Vaccine to HIV-Uninfected Volunteers in the ANRS VAC16 Trial
por: Launay, Odile, et al.
Publicado: (2007) -
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
por: Lévy, Yves, et al.
Publicado: (2020) -
P17-18. ANRS lipo5 sequences induce in vitro cross-reactive CD4+ T cell response against clade B and C
por: Castelli, FA, et al.
Publicado: (2009) -
Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial
por: Gallien, Sébastien, et al.
Publicado: (2014) -
Lipo-Fibroma of the Tonsil
por: Suhrawardy, Hassan
Publicado: (1911)